<?xml version="1.0" encoding="UTF-8"?>
<search_results count="1313">
  <query>SEARCH[STUDY] ( Psoriasis [STUDY:ALL-FIELDS] )</query>
  <clinical_study>
    <order>101</order>
    <score>0.94421</score>
    <nct_id>NCT01636687</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01636687</url>
    <title>Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque-type Psoriasis</condition_summary>
    <intervention_summary>Drug: Placebo; Drug: Secukinumab 150mg; Drug: Secukinumab 300mg</intervention_summary>
    <last_changed>January 30, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>102</order>
    <score>0.94382</score>
    <nct_id>NCT00150982</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00150982</url>
    <title>Alefacept Mechanism of Action in Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Mechanism of action of alefacept</intervention_summary>
    <last_changed>August 6, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>103</order>
    <score>0.94338</score>
    <nct_id>NCT01443338</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01443338</url>
    <title>Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2</title>
    <status open="N">Unknown status</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: Triptergium Wilfordii; Drug: Acitretin</intervention_summary>
    <last_changed>September 28, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>104</order>
    <score>0.94336</score>
    <nct_id>NCT01233583</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01233583</url>
    <title>Regulatory T-cells in Psoriasis Patients as Targets for Therapy</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Dovobet, neotigason, etanercept, adalimumab. infliximab</intervention_summary>
    <last_changed>December 2, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>105</order>
    <score>0.94321</score>
    <nct_id>NCT00705900</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00705900</url>
    <title>LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: LCD; Drug: calcipotriol</intervention_summary>
    <last_changed>November 17, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>106</order>
    <score>0.94305</score>
    <nct_id>NCT02701205</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02701205</url>
    <title>Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Plaque Psoriasis; Psoriasis</condition_summary>
    <intervention_summary>Biological: etanercept; Biological: etanercept (half dose); Drug: placebo</intervention_summary>
    <last_changed>March 7, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>107</order>
    <score>0.94294</score>
    <nct_id>NCT02174354</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02174354</url>
    <title>Methotrexate Polyglutamates as a Marker of Clinical Response and Toxicity in the Treatment of Psoriasis</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Psoriasis Chronic; Injury of Liver</condition_summary>
    <last_changed>June 24, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>108</order>
    <score>0.9428</score>
    <nct_id>NCT02016482</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02016482</url>
    <title>A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Nail Psoriasis; Plaque Psoriasis</condition_summary>
    <intervention_summary>Biological: Adalimumab; Other: Placebo</intervention_summary>
    <last_changed>April 25, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>109</order>
    <score>0.94277</score>
    <nct_id>NCT01328366</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01328366</url>
    <title>Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>June 11, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>110</order>
    <score>0.94269</score>
    <nct_id>NCT01268527</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01268527</url>
    <title>A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: 0.03% E6201; Drug: 0.1% E6201; Drug: 0.2% E6201; Drug: 0.005% E6201; Drug: 0.01% E6201; Drug: 0.05% E6201; Other: Placebo - 0.03% gel vehicle; Other: Placebo - 0.1% gel vehicle; Other: Placebo - 0.2% gel vehicle; Other: Placebo - 0.05% gel vehicle; Other: Placebo - 0.01% gel vehicle; Other: Placebo - 0.05% gel vehicle; Drug: Calcipotriene</intervention_summary>
    <last_changed>April 25, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>111</order>
    <score>0.94249</score>
    <nct_id>NCT00995969</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00995969</url>
    <title>CT 327 in the Treatment of Psoriasis Vulgaris</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: placebo; Drug: CT 327</intervention_summary>
    <last_changed>February 9, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>112</order>
    <score>0.94244</score>
    <nct_id>NCT00454584</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00454584</url>
    <title>An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: CNTO 1275 45 mg; Drug: CNTO 1275 90 mg; Drug: Etanercept 50 mg</intervention_summary>
    <last_changed>October 19, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>113</order>
    <score>0.9422</score>
    <nct_id>NCT00723528</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00723528</url>
    <title>An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Placebo (CP); Drug: Ustekinumab 45 mg (CP); Drug: Ustekinumab 90 mg (CP); Drug: Placebo A (After CP); Drug: Placebo B (After CP); Drug: Ustekinumab 45 mg (After CP); Drug: Ustekinumab 90 mg (After CP)</intervention_summary>
    <last_changed>April 22, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>114</order>
    <score>0.94196</score>
    <nct_id>NCT00593177</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00593177</url>
    <title>A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: PTH (1-34) Gel / Placebo Gel</intervention_summary>
    <last_changed>August 18, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>115</order>
    <score>0.94182</score>
    <nct_id>NCT02749656</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02749656</url>
    <title>Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Scalp Psoriasis</condition_summary>
    <intervention_summary>Drug: 0.25% Desoximetasone cream (Topoxy®); Drug: 0.25% Desoximetasone cream (Topicorte®); Drug: Placebo</intervention_summary>
    <last_changed>April 28, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>116</order>
    <score>0.94174</score>
    <nct_id>NCT01510951</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01510951</url>
    <title>Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: AMG 811 or Placebo</intervention_summary>
    <last_changed>March 25, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>117</order>
    <score>0.94172</score>
    <nct_id>NCT03069144</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03069144</url>
    <title>Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis; Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: HAT1 topical solution; Drug: Calcipotriol</intervention_summary>
    <last_changed>February 27, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>118</order>
    <score>0.94144</score>
    <nct_id>NCT00236171</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00236171</url>
    <title>Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: Protopic, Advantan; Procedure: Blood and Urine Test; Procedure: coherence tomography</intervention_summary>
    <last_changed>June 7, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>119</order>
    <score>0.94123</score>
    <nct_id>NCT00113542</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00113542</url>
    <title>A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Tetrathiomolybdate (TM)</intervention_summary>
    <last_changed>May 20, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>120</order>
    <score>0.94115</score>
    <nct_id>NCT01202565</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01202565</url>
    <title>Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate to Severe Plaque Psoriasis</condition_summary>
    <last_changed>July 15, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>121</order>
    <score>0.94088</score>
    <nct_id>NCT01644396</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01644396</url>
    <title>An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate to Severe Plaque Psoriasis</condition_summary>
    <intervention_summary>Biological: Adalimumab</intervention_summary>
    <last_changed>September 22, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>122</order>
    <score>0.94079</score>
    <nct_id>NCT00773734</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00773734</url>
    <title>Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis; Plaque-type Psoriasis</condition_summary>
    <intervention_summary>Drug: Apremilast 10mg; Drug: Apremilast 20mg; Drug: Apremilast 30 mg; Drug: Placebo; Drug: Apremilast 30mg; Drug: Apremilast 20mg</intervention_summary>
    <last_changed>October 27, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>123</order>
    <score>0.94077</score>
    <nct_id>NCT01522742</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01522742</url>
    <title>Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study</title>
    <status open="N">Terminated</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>March 15, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>124</order>
    <score>0.94058</score>
    <nct_id>NCT00601107</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00601107</url>
    <title>A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate to Severe Chronic Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Doxercalciferol; Drug: Placebo</intervention_summary>
    <last_changed>April 2, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>125</order>
    <score>0.94052</score>
    <nct_id>NCT02905006</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02905006</url>
    <title>Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Chronic Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Bimekizumab; Other: Placebo</intervention_summary>
    <last_changed>August 3, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>126</order>
    <score>0.94043</score>
    <nct_id>NCT01555125</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01555125</url>
    <title>First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate to Severe Plaque-type Psoriasis</condition_summary>
    <intervention_summary>Drug: secukinumab 150 mg; Drug: secukinumab 300 mg; Drug: placebo</intervention_summary>
    <last_changed>February 28, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>127</order>
    <score>0.94023</score>
    <nct_id>NCT01094093</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01094093</url>
    <title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: AMG 139</intervention_summary>
    <last_changed>May 18, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>128</order>
    <score>0.94017</score>
    <nct_id>NCT01702324</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01702324</url>
    <title>Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study</title>
    <status open="N">Unknown status</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: DD-25</intervention_summary>
    <last_changed>October 4, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>129</order>
    <score>0.94008</score>
    <nct_id>NCT01435265</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01435265</url>
    <title>Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Behavioral: Standard nurse education; Behavioral: Additional nurse education</intervention_summary>
    <last_changed>January 24, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>130</order>
    <score>0.93989</score>
    <nct_id>NCT00254982</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00254982</url>
    <title>Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Biological: Infliximab</intervention_summary>
    <last_changed>October 9, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>131</order>
    <score>0.93952</score>
    <nct_id>NCT02004847</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02004847</url>
    <title>Blue Light for Treating Psoriasis Vulgaris</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Device: PSO-CT02</intervention_summary>
    <last_changed>November 17, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>132</order>
    <score>0.93948</score>
    <nct_id>NCT01836939</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01836939</url>
    <title>Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: TSO 2500; Drug: TSO 7500</intervention_summary>
    <last_changed>January 13, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>133</order>
    <score>0.93934</score>
    <nct_id>NCT01262534</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01262534</url>
    <title>A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Other: Clinical profile of patients; Other: Patient Preferences about treatment; Other: Quality of Life</intervention_summary>
    <last_changed>May 3, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>134</order>
    <score>0.9393</score>
    <nct_id>NCT02983981</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02983981</url>
    <title>Topical Psoriasis Study for Patients Receiving Biologic Therapy</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Topicort Topical Spray</intervention_summary>
    <last_changed>December 2, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>135</order>
    <score>0.93927</score>
    <nct_id>NCT01247818</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01247818</url>
    <title>Randomized Study of PH-10 for Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: PH-10 (0.002% Rose Bengal); Drug: PH-10 (0.005% Rose Bengal); Drug: PH-10 (0.01% Rose Bengal); Drug: Vehicle</intervention_summary>
    <last_changed>September 27, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>136</order>
    <score>0.9391</score>
    <nct_id>NCT00333034</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00333034</url>
    <title>Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Etanercept</intervention_summary>
    <last_changed>December 4, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>137</order>
    <score>0.93896</score>
    <nct_id>NCT00320216</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00320216</url>
    <title>A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Ustekinumab; Drug: Placebo</intervention_summary>
    <last_changed>March 31, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>138</order>
    <score>0.93895</score>
    <nct_id>NCT00267969</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00267969</url>
    <title>A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: ustekinumab; Drug: placebo</intervention_summary>
    <last_changed>June 10, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>139</order>
    <score>0.93887</score>
    <nct_id>NCT01511315</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01511315</url>
    <title>The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Ustekinumab</intervention_summary>
    <last_changed>January 13, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>140</order>
    <score>0.9387</score>
    <nct_id>NCT00971477</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00971477</url>
    <title>Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Other: Online Teledermatology Care; Other: Conventional in Office Care</intervention_summary>
    <last_changed>December 9, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>141</order>
    <score>0.93864</score>
    <nct_id>NCT01622348</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01622348</url>
    <title>Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Actively Extending Plaque Psoriasis; Moderate to Severe Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: IMO-3100; Drug: Saline for Injection; Drug: IMO-3100</intervention_summary>
    <last_changed>March 26, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>142</order>
    <score>0.93863</score>
    <nct_id>NCT02295865</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02295865</url>
    <title>A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: JNJ-38518168 60 mg; Drug: JNJ-38518168 30 mg; Drug: JNJ-38518168 3 mg; Drug: Placebo</intervention_summary>
    <last_changed>July 6, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>143</order>
    <score>0.93859</score>
    <nct_id>NCT00770965</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00770965</url>
    <title>Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Plaque Psoriasis</condition_summary>
    <intervention_summary>Biological: AIN457; Biological: Placebo</intervention_summary>
    <last_changed>March 30, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>144</order>
    <score>0.93844</score>
    <nct_id>NCT02201524</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02201524</url>
    <title>Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis</title>
    <status open="N">Terminated</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: PF-04965842; Drug: PF-04965842; Drug: PF-04965842; Other: Placebo</intervention_summary>
    <last_changed>August 11, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>145</order>
    <score>0.93836</score>
    <nct_id>NCT01076192</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01076192</url>
    <title>Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate-to-severe Chronic Plaque Psoriasis</condition_summary>
    <last_changed>December 1, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>146</order>
    <score>0.93828</score>
    <nct_id>NCT01432249</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01432249</url>
    <title>Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Pediatric Psoriasis</condition_summary>
    <intervention_summary>Drug: Enbrel group</intervention_summary>
    <last_changed>November 14, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>147</order>
    <score>0.93798</score>
    <nct_id>NCT02313922</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02313922</url>
    <title>Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate</title>
    <status open="N">Unknown status</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: etanercept combined with methotrexate or etanercept combined with placebo</intervention_summary>
    <last_changed>December 8, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>148</order>
    <score>0.93797</score>
    <nct_id>NCT01708629</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01708629</url>
    <title>Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects</title>
    <status open="N">Terminated</status>
    <condition_summary>Moderate to Severe Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo</intervention_summary>
    <last_changed>November 20, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>149</order>
    <score>0.93797</score>
    <nct_id>NCT01708603</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01708603</url>
    <title>Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects</title>
    <status open="N">Terminated</status>
    <condition_summary>Moderate to Severe Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo</intervention_summary>
    <last_changed>July 27, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>150</order>
    <score>0.93768</score>
    <nct_id>NCT00788424</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00788424</url>
    <title>Topical Application of AS101 for the Treatment of Psoriasis</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Mild to Moderate Psoriasis</condition_summary>
    <intervention_summary>Drug: AS101 Cream</intervention_summary>
    <last_changed>July 22, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>151</order>
    <score>0.93758</score>
    <nct_id>NCT00563524</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00563524</url>
    <title>Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: ILV-094</intervention_summary>
    <last_changed>March 9, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>152</order>
    <score>0.9375</score>
    <nct_id>NCT02826603</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02826603</url>
    <title>Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Secukinumab; Drug: Ustekinumab</intervention_summary>
    <last_changed>January 18, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>153</order>
    <score>0.93746</score>
    <nct_id>NCT01071252</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01071252</url>
    <title>A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Plaque-type Psoriasis</condition_summary>
    <intervention_summary>Drug: AIN457; Drug: Placebo</intervention_summary>
    <last_changed>February 12, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>154</order>
    <score>0.93723</score>
    <nct_id>NCT00307437</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00307437</url>
    <title>A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Drug: Ustekinumab (CNTO 1275) 45 mg; Drug: Ustekinumab (CNTO 1275) 90 mg</intervention_summary>
    <last_changed>January 16, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>155</order>
    <score>0.93706</score>
    <nct_id>NCT02346240</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02346240</url>
    <title>Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Psoriasis; Plaque Psoriasis</condition_summary>
    <intervention_summary>Biological: Certolizumab Pegol; Biological: Etanercept; Other: Placebo</intervention_summary>
    <last_changed>May 3, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>156</order>
    <score>0.93699</score>
    <nct_id>NCT00678470</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00678470</url>
    <title>Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate to Severe Psoriasis</condition_summary>
    <intervention_summary>Drug: Intralesional Alefacept</intervention_summary>
    <last_changed>February 19, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>157</order>
    <score>0.93689</score>
    <nct_id>NCT02999698</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02999698</url>
    <title>Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Psoriasis; Hidradenitis</condition_summary>
    <intervention_summary>Other: Observational</intervention_summary>
    <last_changed>December 21, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>158</order>
    <score>0.93684</score>
    <nct_id>NCT00617994</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00617994</url>
    <title>Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: INCB018424</intervention_summary>
    <last_changed>March 13, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>159</order>
    <score>0.93683</score>
    <nct_id>NCT00669916</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00669916</url>
    <title>A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Biological: AIN457; Drug: Placebo</intervention_summary>
    <last_changed>April 9, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>160</order>
    <score>0.93682</score>
    <nct_id>NCT02326298</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02326298</url>
    <title>An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Psoriasis; Plaque Psoriasis</condition_summary>
    <intervention_summary>Biological: Certolizumab Pegol; Other: Placebo</intervention_summary>
    <last_changed>May 3, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>161</order>
    <score>0.93677</score>
    <nct_id>NCT02326272</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02326272</url>
    <title>A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Psoriasis; Plaque Psoriasis</condition_summary>
    <intervention_summary>Biological: Certolizumab Pegol; Other: Placebo</intervention_summary>
    <last_changed>May 3, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>162</order>
    <score>0.93675</score>
    <nct_id>NCT01072383</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01072383</url>
    <title>Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: BT061; Drug: placebo treatment</intervention_summary>
    <last_changed>March 12, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>163</order>
    <score>0.93647</score>
    <nct_id>NCT01894373</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01894373</url>
    <title>Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis</title>
    <status open="N">Unknown status</status>
    <condition_summary>Psoriasis; Adoptive Immunotherapy</condition_summary>
    <intervention_summary>Drug: Adoptive Immunotherapy; Biological: CIK</intervention_summary>
    <last_changed>July 3, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>164</order>
    <score>0.93641</score>
    <nct_id>NCT02191020</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02191020</url>
    <title>Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Total glucosides of paeony &amp; Acitretin Capsules; Drug: Acitretin Capsules</intervention_summary>
    <last_changed>July 11, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>165</order>
    <score>0.93619</score>
    <nct_id>NCT00350116</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00350116</url>
    <title>Topical Vitamin B12 in Chronic Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: topical vitamin B12</intervention_summary>
    <last_changed>July 6, 2006</last_changed>
  </clinical_study>
  <clinical_study>
    <order>166</order>
    <score>0.93616</score>
    <nct_id>NCT01137448</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01137448</url>
    <title>The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Psoriasis; Obesity</condition_summary>
    <intervention_summary>Behavioral: Weight Loss</intervention_summary>
    <last_changed>December 12, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>167</order>
    <score>0.93598</score>
    <nct_id>NCT00106834</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00106834</url>
    <title>A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Infliximab</intervention_summary>
    <last_changed>May 18, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>168</order>
    <score>0.9359</score>
    <nct_id>NCT00373516</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00373516</url>
    <title>Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Vehicle (Placebo) applied BID; Drug: QRX-101 75 mcg/g ointment applied QD; Drug: QRX-101 75 mcg/g ointment applied BID</intervention_summary>
    <last_changed>September 6, 2006</last_changed>
  </clinical_study>
  <clinical_study>
    <order>169</order>
    <score>0.93572</score>
    <nct_id>NCT02574091</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02574091</url>
    <title>Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: 1% icotinib hydrochloride cream; Drug: 2% icotinib hydrochloride cream; Drug: Placebo</intervention_summary>
    <last_changed>July 12, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>170</order>
    <score>0.93566</score>
    <nct_id>NCT00663052</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00663052</url>
    <title>Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis; Psoriasis</condition_summary>
    <intervention_summary>Drug: Etanercept; Drug: Etanercept</intervention_summary>
    <last_changed>March 29, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>171</order>
    <score>0.93551</score>
    <nct_id>NCT02347501</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02347501</url>
    <title>Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Sitagliptin (Januvia)</intervention_summary>
    <last_changed>April 27, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>172</order>
    <score>0.93549</score>
    <nct_id>NCT03084146</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03084146</url>
    <title>The Role of Food Sensitivity in Psoriasis</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Other: 12-week elimination diet</intervention_summary>
    <last_changed>June 28, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>173</order>
    <score>0.93544</score>
    <nct_id>NCT02940002</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02940002</url>
    <title>BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: BAY1003803; Drug: Clobetasol propionate; Drug: Betamethasone/calcipotriene</intervention_summary>
    <last_changed>March 20, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>174</order>
    <score>0.93519</score>
    <nct_id>NCT01815424</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01815424</url>
    <title>A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: placebo; Drug: CP-690,550; Drug: CP-690,550</intervention_summary>
    <last_changed>August 30, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>175</order>
    <score>0.93518</score>
    <nct_id>NCT00287547</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00287547</url>
    <title>Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: CTLA4Ig / Abatacept</intervention_summary>
    <last_changed>April 11, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>176</order>
    <score>0.9351</score>
    <nct_id>NCT01765985</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01765985</url>
    <title>Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Palm &amp; Soles</condition_summary>
    <intervention_summary>Device: PSORIAMED; Device: PLACEBO</intervention_summary>
    <last_changed>January 13, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>177</order>
    <score>0.93499</score>
    <nct_id>NCT01177800</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01177800</url>
    <title>A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Placebo; Drug: Infliximab</intervention_summary>
    <last_changed>September 4, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>178</order>
    <score>0.93491</score>
    <nct_id>NCT01708590</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01708590</url>
    <title>Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects</title>
    <status open="N">Terminated</status>
    <condition_summary>Moderate to Severe Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: placebo</intervention_summary>
    <last_changed>August 6, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>179</order>
    <score>0.93479</score>
    <nct_id>NCT01162252</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01162252</url>
    <title>Improving Psoriasis Through Health and Well-Being</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Behavioral: Mindfulness-Based Stress Reduction; Behavioral: Living Well</intervention_summary>
    <last_changed>August 12, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>180</order>
    <score>0.93478</score>
    <nct_id>NCT01121081</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01121081</url>
    <title>The Effect of Algae Dunaliella Bardawil on Psoriasis (2)</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Alga Dunaliella Bardawil; Drug: Placebo</intervention_summary>
    <last_changed>January 23, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>181</order>
    <score>0.93476</score>
    <nct_id>NCT00358670</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00358670</url>
    <title>Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)</title>
    <status open="N">Terminated</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Biological: infliximab; Biological: infliximab</intervention_summary>
    <last_changed>March 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>182</order>
    <score>0.93459</score>
    <nct_id>NCT01988103</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01988103</url>
    <title>Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis;; Psoriatic Arthritis;; Psoriasis Arthropatica</condition_summary>
    <intervention_summary>Drug: Apremilast; Drug: Apremilast; Drug: Placebo</intervention_summary>
    <last_changed>April 26, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>183</order>
    <score>0.93441</score>
    <nct_id>NCT01964443</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01964443</url>
    <title>Clinical Assessment and Psychosocial Impact of Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>December 14, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>184</order>
    <score>0.93435</score>
    <nct_id>NCT00585650</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00585650</url>
    <title>Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Biological: Entercept; Other: Placebo injections</intervention_summary>
    <last_changed>October 5, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>185</order>
    <score>0.93435</score>
    <nct_id>NCT03073200</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03073200</url>
    <title>Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Ixekizumab; Drug: Placebo</intervention_summary>
    <last_changed>July 28, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>186</order>
    <score>0.93432</score>
    <nct_id>NCT01646073</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01646073</url>
    <title>Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Biological: Adalimumab; Biological: placebo</intervention_summary>
    <last_changed>January 14, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>187</order>
    <score>0.93426</score>
    <nct_id>NCT00925574</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00925574</url>
    <title>A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: CNTO 1959; Placebo</intervention_summary>
    <last_changed>October 28, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>188</order>
    <score>0.93424</score>
    <nct_id>NCT03099083</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03099083</url>
    <title>Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>July 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>189</order>
    <score>0.9342</score>
    <nct_id>NCT01707368</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01707368</url>
    <title>Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Vulgaris; Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Daivobet® Gel</intervention_summary>
    <last_changed>October 29, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>190</order>
    <score>0.93412</score>
    <nct_id>NCT00669214</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00669214</url>
    <title>A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: efalizumab; Drug: placebo</intervention_summary>
    <last_changed>May 12, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>191</order>
    <score>0.93404</score>
    <nct_id>NCT00769184</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00769184</url>
    <title>Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Corticosteroid; Other: Placebo; Drug: LCD</intervention_summary>
    <last_changed>July 22, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>192</order>
    <score>0.934</score>
    <nct_id>NCT01544595</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01544595</url>
    <title>Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Moderate to Severe Plaque-type Psoriasis</condition_summary>
    <intervention_summary>Drug: Secukinumab (AIN457); Drug: Placebo</intervention_summary>
    <last_changed>April 20, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>193</order>
    <score>0.93385</score>
    <nct_id>NCT00673556</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00673556</url>
    <title>A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: alefacept; Drug: placebo</intervention_summary>
    <last_changed>August 25, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>194</order>
    <score>0.93377</score>
    <nct_id>NCT01422434</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01422434</url>
    <title>LEO 90105 Ointment in Japanese Subjects With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: LEO 90105 = calcipotriol + betamethasone dipropionate; Drug: Dovonex® = calcipotriol; Drug: Rinderon® - DP = betamethasone dipropionate</intervention_summary>
    <last_changed>March 25, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>195</order>
    <score>0.93373</score>
    <nct_id>NCT00674063</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00674063</url>
    <title>A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: alefacept</intervention_summary>
    <last_changed>August 25, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>196</order>
    <score>0.93372</score>
    <nct_id>NCT00333411</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00333411</url>
    <title>Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: BIRT 2584 XX; Drug: Placebo</intervention_summary>
    <last_changed>June 13, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>197</order>
    <score>0.93343</score>
    <nct_id>NCT03202004</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03202004</url>
    <title>GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: GSK2894512 1% cream; Drug: Vehicle cream</intervention_summary>
    <last_changed>July 10, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>198</order>
    <score>0.93339</score>
    <nct_id>NCT00936065</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00936065</url>
    <title>Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate to Severe Psoriasis</condition_summary>
    <intervention_summary>Drug: Etanercept; Drug: Etanercept + Acitretin; Drug: Acitretin</intervention_summary>
    <last_changed>March 12, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>199</order>
    <score>0.93334</score>
    <nct_id>NCT00645905</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00645905</url>
    <title>Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: adalimumab; Drug: placebo for adalimumab</intervention_summary>
    <last_changed>March 26, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>200</order>
    <score>0.93321</score>
    <nct_id>NCT01807520</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01807520</url>
    <title>Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate to Severe Nail Psoriasis</condition_summary>
    <intervention_summary>Biological: secukinumab 150 mg; Biological: secukinumab 300 mg; Biological: Placebo</intervention_summary>
    <last_changed>May 5, 2017</last_changed>
  </clinical_study>
</search_results>
